The Greenrose Holding Company Postpones Second Quarter 2022 Conference Call, Originally Scheduled for August 15, 2022 at 5:00 p.m. ET

The Greenrose Holding Company Postpones Second Quarter 2022 Conference Call, Originally Scheduled for August 15, 2022 at 5:00 p.m. ET

The Greenrose Holding Company Inc. (OTC: GNRS, GNRSW) ("Greenrose" or the "Company"), a multi-state grower and producer of cannabis brands and products announced that it will be postponing its scheduled conference call on Monday, August 15, 2022, at 5:00 p.m. Eastern time to discuss its results for the second quarter ended June 30, 2022.

Greenrose is committed to reporting its second quarter 2022 financial results and providing an update on timing for the rescheduled conference call as soon as practicable. The Company expects to issue revised call details once confirmed.

About The Greenrose Holding Company Inc.
The Greenrose Holding Company Inc. is a multi-state cultivator and producer of cannabis brands and products. Greenrose is driven by cultivation. It is understood that being a leader in the cannabis industry starts with outstanding flower derived from sophisticated genetics and scalable grow methods. Greenrose aims to be a vertically integrated company that looks for scale and horizontal consolidation. For more information, please visit www.greenroseholdings.com .

Investor Relations Contact:
Gateway Group, Inc.
Cody Slach or Jackie Keshner
(949) 574-3860
GNRS@gatewayir.com

Greenrose Contact:
Daniel Harley
Executive Vice President, Investor Relations
(516) 307-0383
ir@greenroseholdings.com


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

GNRS
The Conversation (0)
Greenrose Acquisition

Greenrose Acquisition

Greenrose Acquisition Corp is a blank check company.

Greenrose Acquisition Corp is a blank check company. Keep Reading...
Sona Nanotech's THT Cancer Therapy Preclinical Efficacy Studies Published In Peer-Reviewed Scientific Journal

Sona Nanotech's THT Cancer Therapy Preclinical Efficacy Studies Published In Peer-Reviewed Scientific Journal

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") is pleased to announce that the now complete findings from our previously announced pre-clinical breast cancer and melanoma efficacy studies have been published in the peer-reviewed scientific journal, Frontiers in Immunology.... Keep Reading...
Sona Nanotech's THT Cancer Studies Demonstrates Strong Efficacy in Third Preclinical Study and Plans for First-in-human Early Feasibility Study

Sona Nanotech's THT Cancer Studies Demonstrates Strong Efficacy in Third Preclinical Study and Plans for First-in-human Early Feasibility Study

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") announces results from its most recent preclinical study of its Targeted Hyperthermia Therapy ("THT") which uses the Company's patented, biocompatible gold nanorods ("GNRs") to treat certain solid cancer tumors, shrinking them... Keep Reading...
Sona Nanotech to Showcase Its THT Cancer Therapy at NCL 20th Anniversary Symposium and Provides Corporate Update

Sona Nanotech to Showcase Its THT Cancer Therapy at NCL 20th Anniversary Symposium and Provides Corporate Update

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") is pleased to announce that its Chief Scientific Officer, Dr. Len Pagliaro, has been invited to showcase Sona's developing Targeted Hyperthermia Therapy ("THT") cancer treatment today at the Nanotechnology Characterization... Keep Reading...
Sona Provides Corporate Update on Operating Activities

Sona Provides Corporate Update on Operating Activities

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona"), a nanotechnology life sciences company with proprietary manufacturing technology for biocompatible gold nanorods ("GNRs"), is pleased to provide an update on the status of its current operating activities, notably the... Keep Reading...

Interactive Chart

Latest Press Releases

Related News